Vedolizumab news

All news on Vedolizumab (also known as ENTYVIO): plants, production capacities, investments and involved companies.

9 June 2026

Takeda: FDA accepts sBLA for IV ENTYVIO in pediatric UC and Crohn’s

FDA accepted an sBLA to extend IV vedolizumab (ENTYVIO) to children aged 2+ with moderately to severely active UC and Crohn’s; PDUFA Q1 2027.
19 February 2026

Takeda's Phase 3 Study on Pediatric Ulcerative Colitis

Vedolizumab shows promise in treating pediatric ulcerative colitis, achieving 47.3% remission at 54 weeks, with a safety profile consistent with adult use.
8 January 2026

Takeda and Halozyme Collaborate on Vedolizumab

The partnership aims to enhance vedolizumab delivery for IBD treatment, improving patient care and expanding access with ENHANZE technology.

Who will be producing Vedolizumab in the future?

Find out with chemXplore Alpha

Learn more